Skip to main content
. Author manuscript; available in PMC: 2011 May 7.
Published in final edited form as: Vaccine. 2010 Mar 21;28(21):3706–3713. doi: 10.1016/j.vaccine.2010.03.015

Figure 5.

Figure 5

Papilloma outgrowth after peptide priming/ booster immunization in HLA-A2.1 transgenic rabbits. Nineteen HLA-A2.1 transgenic rabbits were divided into four groups (N=5/per group except four animals for chimeric PADRE -HPVE7/82–90). 100µl of TT helper or PADRE fused peptides together with 25µg of CpG2007 were delivered to HLA-A2.1 transgenic rabbits by intranasal and ocular routes for three times with a two-week interval between immunizations. One week after the final booster immunization, the rabbits were challenged with wild type CRPV and a hybrid CRPV containing HPV16E7/82–90 DNA at left and right back sites. Three days after DNA challenge, the rabbits were given 6 shots of DNA vaccine (half of the normal dose of DNA). The rabbits were monitored for papilloma outgrowth at week 2 after the infection. Significantly smaller papillomas were found in CRPVE1/303–311 peptide immunized rabbits with both adjuvants when compared with corresponding control peptide HPV16E7/82–90(P<0.05, unpaired student t test). No significant difference was found between TT helper vs. PADRE fused CRPVE1/303–311 as found previously noted (P>0.05, unpaired student t test).